LU92523I2 - Antigène sous-unitaire type 2 ORF2 du circovirus porcin et ses dérivés pharmaceutiquement acceptables (PORCILIS PCV) - Google Patents

Antigène sous-unitaire type 2 ORF2 du circovirus porcin et ses dérivés pharmaceutiquement acceptables (PORCILIS PCV)

Info

Publication number
LU92523I2
LU92523I2 LU92523C LU92523C LU92523I2 LU 92523 I2 LU92523 I2 LU 92523I2 LU 92523 C LU92523 C LU 92523C LU 92523 C LU92523 C LU 92523C LU 92523 I2 LU92523 I2 LU 92523I2
Authority
LU
Luxembourg
Prior art keywords
nucleotide sequence
polypeptide
sequence
nucleotide
porcine circovirus
Prior art date
Application number
LU92523C
Other languages
English (en)
French (fr)
Original Assignee
Zoetis W Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9514225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92523(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis W Llc filed Critical Zoetis W Llc
Publication of LU92523I2 publication Critical patent/LU92523I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
LU92523C 1997-12-05 2014-08-18 Antigène sous-unitaire type 2 ORF2 du circovirus porcin et ses dérivés pharmaceutiquement acceptables (PORCILIS PCV) LU92523I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9715396A FR2772047B1 (fr) 1997-12-05 1997-12-05 Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection

Publications (1)

Publication Number Publication Date
LU92523I2 true LU92523I2 (fr) 2014-10-20

Family

ID=9514225

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92523C LU92523I2 (fr) 1997-12-05 2014-08-18 Antigène sous-unitaire type 2 ORF2 du circovirus porcin et ses dérivés pharmaceutiquement acceptables (PORCILIS PCV)
LU92524C LU92524I2 (fr) 1997-12-05 2014-08-18 Protéine ORF2 de circovirus porcin de type 2 et ses dérivés pharmaceutiquement acceptables (IngelvacCircoFLEX)

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU92524C LU92524I2 (fr) 1997-12-05 2014-08-18 Protéine ORF2 de circovirus porcin de type 2 et ses dérivés pharmaceutiquement acceptables (IngelvacCircoFLEX)

Country Status (15)

Country Link
US (43) US6703023B1 (el)
EP (6) EP3002331A1 (el)
AT (1) ATE412664T1 (el)
AU (1) AU1491699A (el)
BE (2) BE2014C050I2 (el)
CY (6) CY1115405T1 (el)
DE (1) DE69840174D1 (el)
DK (5) DK1036180T4 (el)
ES (5) ES2456959T3 (el)
FR (3) FR2772047B1 (el)
HK (5) HK1158694A1 (el)
LU (2) LU92523I2 (el)
NL (2) NL300686I2 (el)
PT (5) PT1036180E (el)
WO (1) WO1999029871A2 (el)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192594B2 (en) 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
AU2003248395B2 (en) * 1997-10-03 2006-03-16 Merial Porcine CircoViruses, vaccines and diagnostic reagents
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
AU2002302120B2 (en) * 1997-10-03 2006-01-19 Merial Porcine circoviruses, vaccines and diagnostic reagents
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
ES2289796T3 (es) * 1997-12-11 2008-02-01 University Of Saskatchewan Virus del sindrome del desmedro post-destete procedente de cerdos.
EP1816200B1 (en) * 1997-12-11 2016-03-09 Merial Postweaning multisystemic wasting syndrome virus for pigs
AU770002B2 (en) * 1998-03-13 2004-02-12 University Of Georgia Research Foundation, Inc., The Vaccines against circovirus infections
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
AU2001238535A1 (en) 2000-02-16 2001-08-27 Large Scale Biology Corporation Rolling circle replicon expression vectors
CN1840656B (zh) 2001-03-27 2010-06-02 萨斯喀彻温大学 培养环状病毒的方法
US7276353B2 (en) * 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
AU2011253941B2 (en) * 2004-12-30 2015-01-29 Boehringer Ingelheim Animal Health USA Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
ES2629679T3 (es) 2004-12-30 2017-08-14 Boehringer Ingelheim Vetmedica, Inc. Composiciones inmunogénicas para PCV2 y métodos para producir composiciones de este tipo
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
TW200643171A (en) * 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
CA2620727C (en) * 2005-09-09 2015-06-16 Intervet International B.V. Porcine circovirus type 2 vaccine
MY180002A (en) 2005-12-29 2020-11-19 Boehringer Ingelheim Vetmedica Inc Multivalent pcv2 immunogenic compositions and methods of producing compositions
PL2371383T3 (pl) 2005-12-29 2016-01-29 Boehringer Ingelheim Vetmedica Inc Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
EP2099927A4 (en) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed METHODS FOR REDUCING FLAMBEES OF DISEASES ASSOCIATED WITH PORCINIC CIRCOVIRUS
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed EFFICIENT PROCESS FOR THE TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS
MX2009006066A (es) * 2006-12-15 2009-06-17 Boehringer Ingelheim Vetmed Tratamiento de cerdos con el antigeno pcv.
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CA2687146C (en) * 2007-05-11 2015-07-21 Temasek Life Sciences Laboratory Limited Production of a homogeneous cell line highly permissive to porcine circovirus type 2 (pcv2) infection
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CA2710247C (en) * 2007-12-21 2014-02-18 Wyeth Llc Methods and compositions for immunizing pigs against porcine circovirus
CA2710558A1 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 virus like particle with foreign amino acid insertion
BRPI0907438A2 (pt) 2008-01-23 2015-08-04 Boehringer Ingelheim Vetmed Composições imunogênicas para mycoplasma hyopneumoniae e pcv2 e métodos para produzir tais composições
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
EP2356132A2 (en) * 2008-10-16 2011-08-17 Pfizer Inc. Torque teno virus (ttv) isolates and compositions
US20100150959A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
BR112012007516A2 (pt) 2009-10-02 2015-09-15 Pioneer Hi Bred Int ácido nucléico isolado, plantas , células vegetais, métodos de redução de produção de etileno em uma planta, de aumento de produtividade em uma planta e de aumento de tolerância à aridez, cassete de expressão e semente
MX2012004448A (es) * 2009-10-16 2012-05-08 Pfizer Clones infecciosos de torque teno virus.
US8846388B2 (en) 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
US20130251719A1 (en) * 2009-10-22 2013-09-26 Tiergesundheitsdienst Bayern E.V. Bone marrow aplasia with haemorrhagic disease in calves caused by novel pathogen
WO2011091389A2 (en) * 2010-01-25 2011-07-28 Blood Systems, Inc. Cyclovirus and method of use
KR20110090711A (ko) * 2010-02-04 2011-08-10 녹십자수의약품(주) 신규한 돼지 써코바이러스 타입 2 및 그의 용도
TWI442935B (zh) 2010-12-22 2014-07-01 Sbc Virbac Ltd 豬第二型環狀病毒（Ｐｏｒｃｉｎｅ Ｃｉｒｃｏｖｉｒｕｓ Ｔｙｐｅ ２）、含彼之免疫組合物、檢測套組及其應用
US9677084B2 (en) 2011-04-29 2017-06-13 Pioneer Hi-Bred International, Inc. Down-regulation of a homeodomain-leucine zipper I-class homeobox gene for improved plant performance
HUP1100470A2 (en) 2011-08-30 2013-03-28 Mezoegazdasagi Biotechnologiai Kutatokoezpont Nanoparticle-based veterinary vaccine
EP2564869A1 (en) 2011-09-02 2013-03-06 Ceva Sante Animale Synthetic capsid proteins and uses thereof
UA113192C2 (xx) 2011-12-06 2016-12-26 Імуногенна композиція проти цирковірусу свиней типу 2 (pcv2)
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
ES2734374T3 (es) * 2013-03-01 2019-12-05 Boehringer Ingelheim Animal Health Usa Inc Cuantificación de composiciones de vacuna
KR102217387B1 (ko) * 2013-03-11 2021-02-19 주식회사 중앙백신연구소 재조합 효모 전세포(yeast whole cell)을 이용한 돼지 써코바이러스(PCV2) 서브유닛 백신과 그의 제조 방법
EP2789346A1 (en) 2013-04-11 2014-10-15 CEVA Santé Animale SA Fusion polypeptides and vaccines
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
KR102319843B1 (ko) 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
DK3052516T3 (da) 2013-10-02 2020-03-23 Boehringer Ingelheim Animal Health Usa Inc PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf
EP3034609A1 (en) 2014-12-19 2016-06-22 Ceva Sante Animale Recombinant swinepox virus and vaccines
EP3254692A1 (en) 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
WO2019032830A1 (en) 2017-08-09 2019-02-14 Dreamwell, Ltd. ADJUSTABLE SUPPORT STRUCTURE
WO2019110822A1 (en) 2017-12-08 2019-06-13 Ceva Sante Animale Recombinant swinepox virus and vaccines
KR20200135505A (ko) 2018-03-26 2020-12-02 베링거 인겔하임 애니멀 헬스 유에스에이 인크. 면역원성 조성물의 제조방법
MX2020013484A (es) 2018-06-11 2021-05-27 Ceva Sante Animale Vacunacion contra circovirus porcinos.
US20230366043A1 (en) * 2020-10-06 2023-11-16 Materials and Machines Corporation of America Method for detection of rna or dna from bological samples
WO2023192936A2 (en) * 2022-03-30 2023-10-05 Fred Hutchinson Cancer Center Systems and methods to produce b cells that express selected antibodies and gene products
CN114736310B (zh) * 2022-06-10 2022-10-28 北京华夏兴洋生物科技有限公司 产生圆环病毒2型病毒样颗粒的蛋白质及生物材料与应用

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US69750A (en) * 1867-10-15 Henry bean
US69233A (en) * 1867-09-24 Joseph r
FR2422956A1 (fr) 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
FR2464269B1 (fr) 1979-08-30 1986-04-18 Anvar Sequence nucleotidique codant l'antigene de surface du virus de l'hepatite b, procede permettant son obtention et antigene obtenu
FR2518755B1 (fr) 1981-12-23 1986-04-11 Pasteur Institut Sonde contenant un acide nucleique modifie et reconnaissable par des anticorps specifiques et utilisation de cette sonde pour detecter et caracteriser une sequence d'adn homologue
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5545412A (en) 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5106733A (en) 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
SU1538305A1 (ru) 1987-07-21 1994-12-15 Всесоюзный государственный научно-контрольный институт ветеринарных препаратов Госагропрома СССР Ассоциированная вакцина против лептоспироза и парвовирусной инфекции свиней
US5069901A (en) 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
EP0454735B1 (en) 1989-01-23 1996-05-22 Auspharm International Limited Vaccine composition
US5811103A (en) 1989-03-19 1998-09-22 Akzo Nobel N.V. Hog cholera virus vaccine and diagnostic
ATE277193T1 (de) 1989-03-21 2004-10-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE69128361T3 (de) 1990-05-29 2006-04-13 Wyeth Holdings Corp. Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
WO1992005255A1 (en) 1990-09-13 1992-04-02 Commonwealth Scientific And Industrial Research Organisation Ovine cytokine genes
GB9023111D0 (en) * 1990-10-24 1990-12-05 Wellcome Found Expression system
DE69132274T2 (de) 1990-11-01 2000-12-14 Univ Iowa State Res Found Inc Methode der bakteriellen attenuierung und impfstoff
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
ES2026827A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
US5580557A (en) * 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US6033904A (en) 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
CA2139756A1 (en) 1992-07-08 1994-01-20 Eric M. Bonnem Use of gm-csf as a vaccine adjuvant
JP3149116B2 (ja) * 1992-10-28 2001-03-26 信越化学工業株式会社 ヒトパルボウイルスのエピトープ関連ペプチド
AU675269B2 (en) * 1992-11-09 1997-01-30 Zonagen, Inc. Materials and methods for immunocontraception
WO1994018311A1 (en) 1993-02-08 1994-08-18 Bayer Corporation Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
AU6672994A (en) 1993-05-14 1994-12-12 Mds Health Group Ltd. Electronic worksheet system for microbiology testing and reporting
JPH09500013A (ja) 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
GB2285766B (en) 1994-01-21 1997-07-23 Ecc Int Ltd Ceramic casting composition
KR0121105B1 (ko) * 1994-02-04 1997-11-10 문정환 선입선출메모리 버스장치
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
EP0968722B1 (en) 1994-05-10 2007-06-20 Wyeth Improved modified live BRSV vaccine
GB2289279B (en) 1994-05-13 1998-09-16 Iberica Cyanamid Diagnostic kits and vaccines containing recombinant PRRSV proteins
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US6043232A (en) 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5681658A (en) * 1995-05-30 1997-10-28 Aluminum Company Of America Gelation-resistant alumina
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
CA2221570A1 (en) 1995-06-07 1996-12-19 Aesculaap B.V. Neutralizing conformation epitopes of chicken anemia virus
US5795872A (en) 1995-09-19 1998-08-18 Pharmadigm, Inc. DNA construct for immunization
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
EP0835930B1 (en) 1996-10-09 2001-01-31 Akzo Nobel N.V. European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV)
WO1998040499A1 (en) 1997-03-10 1998-09-17 Heather Lynn Davis Gene delivery to mucosal epithelium for immunization or therapeutic purposes
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US20030215445A1 (en) * 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
FR2769321B1 (fr) 1997-10-03 2001-10-26 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US7192594B2 (en) * 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6143334A (en) * 1997-10-03 2000-11-07 Sargento Foods Inc. Pasta filata method for manufacturing Swiss-type cheeses
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2769322B1 (fr) 1997-10-03 2002-03-08 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
US6165493A (en) 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
ES2289796T3 (es) * 1997-12-11 2008-02-01 University Of Saskatchewan Virus del sindrome del desmedro post-destete procedente de cerdos.
AU770002B2 (en) * 1998-03-13 2004-02-12 University Of Georgia Research Foundation, Inc., The Vaccines against circovirus infections
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
AU1131200A (en) 1998-10-23 2000-05-15 Heska Corporation Cationic lipid-mediated enhancement of nucleic acid immunization of cats
US6143333A (en) 1998-11-13 2000-11-07 Purina Mills, Inc. Method of preparing a packaged fish attractant block
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6179461B1 (en) 1999-09-03 2001-01-30 Davis-Standard Corporation Extruder screw
US6139179A (en) 1999-09-03 2000-10-31 Davis-Standard Corporation Extruder screw having multi-channeled barrier section
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2001017556A1 (fr) 1999-09-07 2001-03-15 Shionogi & Co., Ltd. Préparations vaccinales administrables par les muqueuses
AU771225B2 (en) * 1999-11-10 2004-03-18 Rodenstock Gmbh Heterocyclically anellated indenochromene derivatives
US6366601B1 (en) * 1999-11-17 2002-04-02 Motorola, Inc. Variable rate spread spectrum communication method and apparatus
US7233407B1 (en) * 2000-02-02 2007-06-19 Xerox Corporation Document production system for capturing web page content
JP3363419B2 (ja) * 1999-12-24 2003-01-08 住友ゴム工業株式会社 重荷重用ラジアルタイヤ
WO2001096377A2 (en) 2000-06-15 2001-12-20 Purdue Research Foundation Vaccine for congenital tremors in pigs
JP4768106B2 (ja) 2000-07-31 2011-09-07 スリーエム イノベイティブ プロパティズ カンパニー 接着剤組成物及び熱剥離容易な接着構造
DE10044646A1 (de) 2000-09-08 2002-04-04 Horsch Maschinen Gmbh Spritzgestängeführung
DE10044648A1 (de) 2000-09-08 2002-03-21 Aventis Behring Gmbh Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material
DE10051562A1 (de) * 2000-10-18 2002-04-25 Emitec Emissionstechnologie Beheizbarer Wabenkörper mit zwei verschiedenen Beschichtungen
US6572081B2 (en) * 2000-12-27 2003-06-03 Nkf Kabel B.V. Installation of guide tubes in a protective duct
CN1840656B (zh) * 2001-03-27 2010-06-02 萨斯喀彻温大学 培养环状病毒的方法
AUPR567401A0 (en) 2001-06-14 2001-07-12 University Of Melbourne, The Circovirus vaccines
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US20030215455A1 (en) 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
CA2507520C (en) * 2002-11-28 2007-01-23 Research In Motion Limited Multiple-band antenna with patch and slot structures
US7288529B2 (en) * 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same
SG144909A1 (en) 2003-07-25 2008-08-28 Boehringer Ingelheim Vetmed Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof
US20050279889A1 (en) 2004-06-08 2005-12-22 Safe Flight Instrument Corporation Variable wing spacecraft
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
ES2343201T3 (es) * 2005-01-13 2010-07-26 Boehringer Ingelheim Vetmedica Gmbh Vacunas contra el srrp.
CA2604691C (en) * 2005-04-13 2013-12-31 Merial Limited Method for porcine circovirus production and assays for monitoring production
PL2371383T3 (pl) * 2005-12-29 2016-01-29 Boehringer Ingelheim Vetmedica Inc Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
US8377070B2 (en) * 2007-05-17 2013-02-19 Michael T. Gauthier Compressor distractor tool
US8214576B2 (en) 2009-03-03 2012-07-03 Vmware, Inc. Zero copy transport for target based storage virtual appliances

Also Published As

Publication number Publication date
US20100221276A1 (en) 2010-09-02
US20100189734A1 (en) 2010-07-29
US20080233147A1 (en) 2008-09-25
CY2014036I2 (el) 2016-04-13
CY2014035I2 (el) 2016-04-13
DK1036180T3 (da) 2009-03-09
US20100226934A1 (en) 2010-09-09
US7148015B2 (en) 2006-12-12
FR14C0062I2 (fr) 2016-06-24
LU92524I2 (fr) 2014-10-20
US7179472B2 (en) 2007-02-20
US7261898B2 (en) 2007-08-28
US7740865B2 (en) 2010-06-22
US7604808B2 (en) 2009-10-20
US20070048780A1 (en) 2007-03-01
US20100221283A1 (en) 2010-09-02
EP1992696A1 (fr) 2008-11-19
US20100172924A1 (en) 2010-07-08
PT1036180E (pt) 2009-02-10
CY2014035I1 (el) 2016-04-13
EP2000535A1 (fr) 2008-12-10
PT2330188E (pt) 2015-10-23
US7390494B2 (en) 2008-06-24
US7323330B2 (en) 2008-01-29
US20090092627A1 (en) 2009-04-09
US20060222663A1 (en) 2006-10-05
US20120005768A1 (en) 2012-01-05
US20070041989A1 (en) 2007-02-22
US20100215690A1 (en) 2010-08-26
FR14C0061I1 (el) 2014-10-10
EP1036180B1 (fr) 2008-10-29
AU1491699A (en) 1999-06-28
US8415525B2 (en) 2013-04-09
US10052375B2 (en) 2018-08-21
DK1036180T4 (da) 2012-01-23
EP2316925B1 (fr) 2015-07-08
US20100203072A1 (en) 2010-08-12
PT2000535E (pt) 2014-05-02
US20070065925A1 (en) 2007-03-22
US8124723B2 (en) 2012-02-28
US20100189735A1 (en) 2010-07-29
NL300685I1 (el) 2014-08-27
US6703023B1 (en) 2004-03-09
DK2330188T3 (da) 2015-10-19
US20150175668A1 (en) 2015-06-25
US20050008651A1 (en) 2005-01-13
ES2548145T3 (es) 2015-10-14
US9717784B2 (en) 2017-08-01
FR2772047A1 (fr) 1999-06-11
FR2772047B1 (fr) 2004-04-09
HK1125676A1 (en) 2009-08-14
ES2548146T3 (es) 2015-10-14
CY1115424T1 (el) 2016-04-13
EP1992696B1 (fr) 2014-02-19
US20110033489A1 (en) 2011-02-10
ES2317679T5 (es) 2012-02-24
EP1036180B2 (fr) 2011-11-02
US20040265848A1 (en) 2004-12-30
US20120034630A1 (en) 2012-02-09
US20100189743A1 (en) 2010-07-29
US20070059324A1 (en) 2007-03-15
US20100074919A1 (en) 2010-03-25
US7741026B2 (en) 2010-06-22
BE2014C049I2 (en) 2018-07-04
ES2456959T3 (es) 2014-04-24
NL300685I2 (nl) 2022-03-22
US20040091502A1 (en) 2004-05-13
US20040161410A1 (en) 2004-08-19
DE69840174D1 (de) 2008-12-11
CY2014036I1 (el) 2016-04-13
HK1222415A1 (zh) 2017-06-30
US20090123490A1 (en) 2009-05-14
FR14C0061I2 (fr) 2016-06-24
ATE412664T1 (de) 2008-11-15
US20090162918A1 (en) 2009-06-25
US20040076635A1 (en) 2004-04-22
US20100209453A1 (en) 2010-08-19
BE2014C050I2 (en) 2018-07-04
US20060083756A1 (en) 2006-04-20
HK1158254A1 (en) 2012-07-13
US20070059325A1 (en) 2007-03-15
US7244433B2 (en) 2007-07-17
US20100189733A1 (en) 2010-07-29
HK1126522A1 (en) 2009-09-04
PT2316925E (pt) 2015-10-23
WO1999029871A3 (fr) 1999-08-19
CY1116761T1 (el) 2017-03-15
ES2458309T3 (es) 2014-04-30
US7223594B2 (en) 2007-05-29
US20100166791A1 (en) 2010-07-01
CY1115405T1 (el) 2017-01-04
US20150182616A1 (en) 2015-07-02
US20110135677A1 (en) 2011-06-09
US7405075B2 (en) 2008-07-29
US7758865B2 (en) 2010-07-20
US9700613B2 (en) 2017-07-11
HK1158694A1 (en) 2012-07-20
US7951907B2 (en) 2011-05-31
EP1036180A2 (fr) 2000-09-20
US20100189736A1 (en) 2010-07-29
EP2000535B1 (fr) 2014-01-22
PT1992696E (pt) 2014-05-27
US20070041990A1 (en) 2007-02-22
US7425444B2 (en) 2008-09-16
US20070253971A1 (en) 2007-11-01
EP3002331A1 (fr) 2016-04-06
EP2316925A1 (fr) 2011-05-04
US7740866B2 (en) 2010-06-22
EP2330188A1 (fr) 2011-06-08
DK1992696T3 (da) 2014-05-19
CY1116837T1 (el) 2017-03-15
NL300686I2 (nl) 2022-03-22
WO1999029871A2 (fr) 1999-06-17
US7407803B2 (en) 2008-08-05
FR14C0062I1 (el) 2014-10-10
US8715690B2 (en) 2014-05-06
US20180000927A1 (en) 2018-01-04
DK2000535T3 (da) 2014-04-22
US20100189732A1 (en) 2010-07-29
US20050084497A1 (en) 2005-04-21
US20070110767A1 (en) 2007-05-17
ES2317679T3 (es) 2009-04-16
NL300686I1 (el) 2014-08-27
EP2330188B1 (fr) 2015-07-15
DK2316925T3 (da) 2015-10-12
US8916353B2 (en) 2014-12-23
US7722883B2 (en) 2010-05-25
US7297537B2 (en) 2007-11-20

Similar Documents

Publication Publication Date Title
LU92523I2 (fr) Antigène sous-unitaire type 2 ORF2 du circovirus porcin et ses dérivés pharmaceutiquement acceptables (PORCILIS PCV)
Moormann et al. Molecular cloning and nucleotide sequence of hog cholera virus strain Brescia and mapping of the genomic region encoding envelope protein E1
de Turiso et al. Fine mapping of canine parvovirus B cell epitopes
JP2703538B2 (ja) 偽狂犬病ウイルス突然変異体、それを含有するワクチン、その生産法およびその使用法
JP2001511347A5 (el)
JP2004508043A5 (el)
Majhdi et al. Isolation and characterization of a coronavirus from elk calves with diarrhea
Vasudevacharya et al. The NS and capsid genes determine the host range of porcine parvovirus
JP2000184889A (ja) ウイルス検出用プライマ―
Vanderheijden et al. Expression of the bovine viral diarrhoea virus Osloss p80 protein: its use as ELISA antigen for cattle serum antibody detection
Grove et al. Serum immunoglobulin M in Atlantic halibut (Hippoglossus hippoglossus): characterisation of the molecule and its immunoreactivity
PARK et al. Identification of VP3 as an important neutralising epitope from DRT strain, a Korean isolate of infectious pancreatic necrosis virus (IPNV)
JP2003507029A5 (el)
KR100563197B1 (ko) 개 파보바이러스 중화항원 결정기를 포함하는 ｖｐ2재조합 단백질 및 이를 포함하는 백신 조성물
CN107365367A (zh) A型口蹄疫病毒vp1蛋白抗原表位基因多肽及其应用
Greiser-Wilke et al. Distribution of cytopathogenic and noncytopathogenic bovine virus diarrhea virus in tissues from a calf with experimentally induced mucosal disease using antigenic and genetic markers: Brief Report
O'Connor et al. The major product of porcine transmissible gastroenteritis coronavirus gene 3b is an integral membrane glycoprotein of 31 kDa
JP2007534311A (ja) Ｂｒａｃｈｙｓｐｉｒａｐｉｌｏｓｉｃｏｌｉ７２ｋＤａ外膜タンパク質及び診断及び治療のためのその使用
Vihinen-Ranta et al. Detection of canine parvovirus antigens with antibodies to synthetic peptides
JP2006517384A5 (el)
Zhao Molecular characterization and humoral immunity of bovine rotavirus VP4, VP6, and VP7
FR2808277A1 (fr) Polypeptide du ttv, acide nucleique codant pour ce polypeptide et utilisations
Blomster Localization of immunobiological sites on toxic shock syndrome toxin-1
SCHIFF ORIGIN AND PROPERTIES OF THE 32,000-DALTON ENDONUCLEASE FROM AVIAN RETROVIRUS CORES